Category Archives: DNA

OKLAHOMA CITY (KFOR) In the cold case murder trial of Robert Hashagen, investigators say its DNA evidence that finally proved he killed 94-year-old Evelyn Goodall. His attorneys argue the evidence is not even enough to prove it came from him.

Goodall was severely beaten by someone who broke into her home in 2013.

On Thursday, DNA analysts for the state said what could be his DNA was found on a toilet paper roll and in a yellow liquid that may have been urine at the crime scene.

They also allege that what could be his DNA was found on a bra in her home after she was previously attacked by someone in 2010.

I dont agree with the characterization that our DNA is in the home, said Hashagens attorney Clay Curtis. I think that is misstating the nature of the evidence.

The DNA analysts said Hashagen could not be ruled out as the person the DNA samples came from when comparing them to a DNA he provided investigators.

His attorneys argue the DNA found on on those items could have come from any number of people.

However, they also said that because Goodall and Hashagen knew each other, there are other legitimate reasons his DNA might be found around her home, including that he went to her home a couple days after she was attacked to help fix her screen door.

She borrowed our fan, Curtis said. We had been over there numerous times, we know her. Our family knows her.

But in addition to the DNA, the state also called an Oklahoma County Detention Center inmate to testify that Hashagen admitted to the murder during a conversation in jail.

The informant said that Hashagen bragged that some of the DNA evidence was botched. According to the inmate, Hashagen said he got high on meth and went to her home to steal something from her, and that when he went to tie her up, he tore the hide off her wrists. He recalled Hashagen say, Really, she murdered herself.

Defense attorneys suggested the inmate only testified in order to get a better deal with the state to help himself.

On Friday, the detective who picked up the case after it went cold is expected to conclude the states case.

Read more from the original source:
DNA analysts and an Oklahoma County Jail informant testify in trial of accused killer of 94-year-old woman - KFOR Oklahoma City

NYU College of Dentistry clinician-scientists Seiichi Yamano and Brian Schmidt have set out to develop a new class of medicines using gene therapy to effectively and safely treat oral cancer pain. The National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health (NIH), has awarded the researchers a five-year, $2.9 million grant (R01DE029694) to test whether nonviral co-delivery of DNA and RNA will safely alleviate oral cancer pain.

Patients with oral cancer often suffer from severe pain. These patients may find it difficult to eat, drink, or even talk. The opioid medications used to treat oral cancer pain become less effective as patients develop drug tolerance, and cause numerous debilitating side effects.

Gene therapy offers an alternative to opioids for the treatment of cancer pain by reversing cancer-induced epigenetic changes. This approach selectively disrupts pain signaling without the side effects of opioids.

Complete elimination of cancer pain in a patient is exceptionally challenging because there are multiple and redundant pain-signaling mechanisms and pathways, explained Schmidt, who is a professor in the Department of Oral and Maxillofacial Surgery at NYU College of Dentistry as well as the director of NYUs Bluestone Center for Clinical Research and the NYU Oral Cancer Center.

As a strategy to obstruct these multiple and varied pathways, Yamano and Schmidt created two nonviral vectors that can efficiently deliver DNA and RNA to cells (transfection) with no toxicity: a cell-permeable peptide combined with a cationic lipid for DNA, and a lipopolymer for RNA. They hypothesize that the combination of OPRM1 (mu opioid receptor gene) re-expression and F2RL1 (gene for protease-activated receptor-2, or PAR2) downregulation in the cancer could eliminate cancer pain.

In preliminary studies, Yamano and Schmidt demonstrated that nonviral transfection with OPRM1 DNA led to re-expression of the mu opioid receptor and partial reduction of pain in preclinical cancer models. PAR2was found to be elevated in certain neurons that supply the cancer with nerves and drive pain. Knockdown of the F2RL1 gene partially attenuated pain.

In their newly funded NIH grant, the researchers will test whether the combination of OPRM1 re-expression and F2RL1 downregulation in the cancer can go beyond reducing cancer pain to eliminate it.

Our approach is innovative because delivering DNA and RNA into a cancer with nonviral vectors for the management of pain has not been done before, said Yamano, an associate professor of prosthodontics at NYU College of Dentistry. If we are successful, the knowledge generated through this research could set the stage for a clinical trial and ultimately lead to the development of novel non-opioid medicines for cancer pain.

Yamano and Schmidt have collaborated on this work over the last decade; their efforts have been supported by three previous NIH-funded grants.

About NYU College of DentistryFounded in 1865, New York University College of Dentistry (NYU Dentistry) is the third oldest and the largest dental school in the US, educating nearly 10 percent of the nations dentists. NYU Dentistry has a significant global reach with a highly diverse student body. Visit http://dental.nyu.edu for more.

Read the original post:
NYU Dentistry Awarded NIH Grant to Investigate Oral Cancer Pain Treatment Utilizing Co-delivery of DNA and RNA - NYU News

Wall Street expects a year-over-year increase in earnings on higher revenues when Applied DNA Sciences (APDN) reports results for the quarter ended December 2020. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.

The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus Estimate

This DNA-based security technology company is expected to post quarterly loss of $0.55 per share in its upcoming report, which represents a year-over-year change of +50.9%.

Revenues are expected to be $1.40 million, up 122.2% from the year-ago quarter.

Estimate Revisions Trend

The consensus EPS estimate for the quarter has been revised 40.54% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings Whisper

Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Story continues

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Applied DNA Sciences?

For Applied DNA Sciences, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate. This has resulted in an Earnings ESP of 0%.

On the other hand, the stock currently carries a Zacks Rank of #3.

So, this combination makes it difficult to conclusively predict that Applied DNA Sciences will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?

While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Applied DNA Sciences would post a loss of $0.59 per share when it actually produced a loss of $0.82, delivering a surprise of -38.98%.

The company has not been able to beat consensus EPS estimates in any of the last four quarters.

Bottom Line

An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Applied DNA Sciences doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Applied DNA Sciences Inc (APDN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Originally published January 28, 2021, 12:32 PM

View original post here:
Will Applied DNA Sciences (APDN) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance

DNA, or deoxyribonucleic acid, is the hereditary material in humans and almost all other organisms. Nearly every cell in a persons body has the same DNA. Most DNA is located in the cell nucleus (where it is called nuclear DNA), but a small amount of DNA can also be found in the mitochondria (where it is called mitochondrial DNA or mtDNA). Mitochondria are structures within cells that convert the energy from food into a form that cells can use.

The information in DNA is stored as a code made up of four chemical bases: adenine (A), guanine (G), cytosine (C), and thymine (T). Human DNA consists of about 3 billion bases, and more than 99 percent of those bases are the same in all people. The order, or sequence, of these bases determines the information available for building and maintaining an organism, similar to the way in which letters of the alphabet appear in a certain order to form words and sentences.

DNA bases pair up with each other, A with T and C with G, to form units called base pairs. Each base is also attached to a sugar molecule and a phosphate molecule. Together, a base, sugar, and phosphate are called a nucleotide. Nucleotides are arranged in two long strands that form a spiral called a double helix. The structure of the double helix is somewhat like a ladder, with the base pairs forming the ladders rungs and the sugar and phosphate molecules forming the vertical sidepieces of the ladder.

An important property of DNA is that it can replicate, or make copies of itself. Each strand of DNA in the double helix can serve as a pattern for duplicating the sequence of bases. This is critical when cells divide because each new cell needs to have an exact copy of the DNA present in the old cell.

Visit link:
What is DNA?: MedlinePlus Genetics

Jan. 15, 2021 12:00 UTC

STONY BROOK, N.Y.--(BUSINESS WIRE)-- Applied DNA Sciences, Inc.(NASDAQ:APDN) (the Company), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that its safeCircle pooled surveillance testing service has seen a 158% increase in the daily average number of tests performed to date in January 2021 compared to December 2020. The increase is chiefly the result of the scale-up of certain testing contracts and from the acquisition of new clients. Launched in the fourth quarter of fiscal 2020 (ended September 30, 2020), safeCircle now counts 33 primary/secondary/higher education institutions, private client, local government, and businesses as clients.

Concurrently, the Company stated that it is increasing production of its Linea COVID-19 Assay Kit (the Assay Kit) and sample collection kits to meet expected demand from existing customers, from its safeCircle service that is powered by the Assay Kit, and due to heightened interest in the Assay Kit following a recent U.S. Food & Drug Administrations Food & Drug Administration (FDA) alert that identified the assay as an EUA-approved molecular diagnostic test that can potentially identify certain SARS-CoV-2 mutations (the FDA Alert). The Company also said that Applied DNA Clinical Laboratories, LLC (ADCL), its wholly-owned subsidiary, is on track to submit a request for CLEP-CLIA re-inspection during the current quarter ending March 31, 2021. If granted, CLEP-CLIA certification would enable ADCL to serve as a diagnostic laboratory that would allow for it to conduct diagnostic COVID-19 testing.

Positive business trends for safeCircle have carried over into January and are further enhanced by the growing awareness of our platform regionally and through our partnership with CLEARED4. The profile of prospective clients is changing with more and larger opportunities in our sales pipeline, said Dr. James A. Hayward, president and CEO.

The FDAs recent Alert has the potential to be a catalyst to revenue, concluded Dr. Hayward. We believe our assay is one of the few cost-effective and rapid ways a laboratory can detect S-gene target dropout that serves as a potential indication of a SARS-CoV-2 variant, including the U.K.s B.1.1.7 that is characterized by increased transmissibility. We believe the ability to identify new potential COVID-19 variants with an EUA-approved molecular diagnostic test that is in-market today is essential in the continuing fight against COVID-19. Diagnostic labs using molecular diagnostic tests that do not have the ability to discriminate potential COVID-19 variants from wildtype are unable to quickly and easily identify patients that are potentially infected with a more infectious variant, which we believe may lead to further infection spread.

safeCircle Pooled Surveillance Testing Service

In recent weeks safeCircle has added new clients. They include:

Ramp Up in Production of Kits utilized in COVID-19 Sample Collection

The Company is also increasing the production of sample collection kits utilized in surveillance testing by a factor of four to meet the testing scale-up of the Assay Kits largest customer and for use by new safeCircle clients.

CLEARED4 Partnership Generating New Clients

Applied DNAs recently announced partnership with CLEARED4, a provider of return-to-work health safety solutions, has begun to bear fruit. In addition to being utilized as a mobile-friendly, value-added option for the management of aggregate results testing and reporting to a key safeCircle client, Applied DNA is now providing CLEARED4 services to a second safeCircle client, the aforementioned jewelry company. Applied DNA expects to onboard a third new client this week, the aforementioned private higher education institution. The Company believes that the combination of its safeCircle offering with the CLEARED4 platform is a compelling service in a marketplace that is in search of an accurate, easy-to-employ, faster-turnaround testing service that incents participation.

Linea COVID-19 Assay Kit (Test) Production

The Companys largest customer for its Assay Kit expects to increase its use of the Assay and sample collection kits for its in-house surveillance testing program beginning in early February 2021 to coincide with its campus reopening for the Spring semester. The customers in-house program oversees the weekly surveillance testing of thousands of faculty and staff for the presence of COVID-19. Applied DNA receives recurring replenishment orders from the customer for both Assay and sample collection kits to meet its in-house surveillance testing needs.

In response to the FDA Alert, the Company is relaunching its sales and marketing strategy to center on the Assay Kits potential ability to signal for the presence of a SARS-CoV-2 variant due to S-gene target dropout. Refreshed Frequently Asked Questions are available for reference for prospective diagnostic laboratory customers nationally at https://adnas.com/sars-cov-2-69-70del-mutation-covid-assay-kit/.

Update on Applied DNA Clinical Laboratories (ADCL) CLEP-CLIA Certification

The Company is in the process of completing remediation of deficiencies in ADCLs clinical standard of practice and expects to submit a request for re-inspection during the current quarter ending March 31, 2021. CLEP-CLIA certification will enable ADCL to capture diagnostic COVID-19 revenues currently being conducted by third party clinical labs. CLEP-CLIA certification would also potentially allow ADCL to develop an additional revenue stream through the development and commercialization of a broad-array of diagnostic tests, as laboratory-developed tests (LDTs), that once approved by the applicable regulatory authority, could be offered by ADCL.

About the Linea COVID-19 Assay Kit and Pooled Surveillance Testing

The Linea COVID-19 Assay Kit is authorized by FDA EUA for the qualitative detection of nucleic acid from SARS-CoV-2 in respiratory specimens, including anterior nasal swabs, self-collected at a healthcare location or collected by a healthcare worker, and nasopharyngeal and oropharyngeal swabs, mid-turbinate nasal swabs, nasopharyngeal washes/aspirates or nasal aspirates, and bronchoalveolar lavage (BAL) specimens collected by a healthcare worker from individuals who are suspected of COVID-19 by their healthcare provider. The scope of the Linea COVID-19 Assay Kit EUA, as amended, is expressly limited to use consistent with the Instructions for Use by authorized laboratories, certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform high complexity tests. The EUA will be effective until the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 is terminated or until the EUAs prior termination or revocation. The diagnostic kit has not been FDA cleared or approved, and the EUAs limited authorization is only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens.

The Company is offering surveillance testing in compliance with current CDC, FDA, and CMS guidances. The use of saliva and pooled sampling for surveillance testing, which has been internally validated by the Company in compliance with current surveillance testing guidances, is not included in the Companys EUA authorization for the Linea COVID-19 Assay Kit.

About Applied DNA Sciences

Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping, and pre-clinical nucleic acid-based therapeutic drug candidates.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

The Companys common stock is listed on NASDAQ under ticker symbol APDN, and its publicly traded warrants are listed on OTC under ticker symbol APPDW.

Applied DNA is a member of the Russell Microcap Index.

Forward-Looking Statements

The statements made by Applied DNA in this press release may be forward-looking in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNAs future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, limited market acceptance, the possibility that the assay kit could become obsolete or have its utility diminished, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNAs or its partners diagnostic candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration (U.S. FDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, the unknown outcome of any applications or requests to U.S. FDA, equivalent foreign regulatory agencies and/or the New York State Department of Health, the unknown limited duration of any Emergency Use Authorization (EUA) approval from U.S. FDA, changes in guidances promulgated by the CDC, U.S. FDA and/or CMS relating to COVID-19 surveillance and diagnostic testing, disruptions in the supply of raw materials and supplies, and various other factors detailed from time to time in Applied DNAs SEC reports and filings, including our Annual Report on Form 10-K filed on December 17, 2020, and other reports we file with the SEC, which are available at http://www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210115005079/en/

Read the original post:
Applied DNA Provides Business Update on COVID-19 Diagnostics and Testing - BioSpace

Autoplay

Show Thumbnails

Show Captions

Detroit There may not be a more fitting day to introduce or reintroduce for fans of a more aged vintage new Tigers bench coach George Lombard than on Martin Luther King Day. That's because the late Posy Lombard, a white woman from a wealthy New England family who became a legendary activist in the American civil rights movement, is his mother.

Posy Lombard, who was killed in a car accident at age 41, when George was 10, marched with Dr. King in 1963. She was a congressional intern. She went to civil rights seminars to hear Malcolm X. She was arrested in Montgomery, Ala., in 1965, for protesting the Bloody Sunday beatings in Selma. Later she was arrested twice for protesting racial injustice in Natchez, Miss., where she famously stared down members of the Ku Klux Klan that blocked her attempts at integrating a neighborhood playground. She helped affect positive change in the Deep South.

George Lombard was hired as bench coach by new Tigers manager AJ Hinch.(Photo: Elsa, Getty Images)

Your mom was a bad-ass, former Tiger David Price texted Lombard during the baseball shutdown last summer.

The mention of that text raised goosebumps on George Lombards arms Sunday during a Zoom interview.

More: Tigers sign former Red Sox lefty Robbie Ross to minor-league deal

Just being a difference-maker, said Lombard, who spent the last five years going to three World Series and winning one with the Los Angeles Dodgers last October. Jackie Robinson. Martin Luther King. My mom lived such a short life and impacted so many people.

With my story coming out, it was just a chance to change some minds and to move so many people.

More: Tigers splash cash in signing 17-year-old international shortstops Santana, Bastidas

Lombard, though certainly aware of his mothers history his older brother and younger sister worked to obtain a thick file the FBI had on his Posy had never made her story public, never made it part of his story.

Until COVID-19 happened. Until Ahmaud Arbery, Jacob Black and George Floyd happened. Until Black Lives Matter happened.

A police booking photo of Posy Lombard after she was arrested in Montgomery, Alabama.(Photo: Los Angeles Daily News)

Here we are, 50 years later, and were still fighting the same fight, he said. Which is a bit embarrassing. We all need to wake up and understand what is happening.

Lombard, who played for the Tigers in 2002, spent the early days of the pandemic researching his mothers life. He knew he wanted to use her story as a base for his own advocacy efforts. He knew, as a big-league coach, he had a platform. It just wasnt in his nature to jump up on that platform and speak to large groups.

More: Tigers avoid arbitration with all nine eligible players

Especially about his childhood. Posy was raising the three children by herself. All of a sudden, she was gone and their father, Paul Williams, an autoworker who had been living elsewhere, was moving back in. Lombard remembers being in an Atlanta courtroom and a judge asking him if he wanted to keep the name Lombard or use their fathers name Williams.

More: Ex-Tigers help throw iconic Detroit columnist Pete Waldmeir a 90th birthday bash

Those are tough questions to answer at a young age, he said. But Im 45 now and I realize the decisions Ive made throughout my life had a great deal to do with the way my mother raised us.

Lombard, with the help of renowned mental skills trainer Lucas Jadin, gradually started bringing his and his mothers story into the light. First a feature story in the Los Angeles Daily News. Then ESPN gave it a national ride. Within the clubhouse, Price was the first one Lombard opened up to about it.

Former Tigers pitcher David Price was instrumental in telling players the story of George Lombard's mother Posy, who was a strong advocate in the fight for civil rights.(Photo: Carlos Osorio, AP)

Pricey was great, he was the one who really pushed the story to the players, Lombard said.

After taking part in a peaceful march for justice in Scottsdalethis summer, Price, as reported in the ESPN story, texted Lombard: George, I just wanted to let you know that my family and I did a peaceful protest in honor of your mom's name. I can't tell you how many shapes, sizes, colors, religions, ethnicities however you identify, everybody was out there. We were together as one, and that's the way it needs to be."

More: Power up: Tigers pitcher Michael Fulmer done being skinny

Lombard told ESPN, "I told my wife it was my greatest moment as a coach. I was almost in tears."

Its been the most emotional six months that Ive had, Lombard said on Sunday.

Culminating, of course, with a World Series championship with the Dodgers.

I was part of five years in L.A. where we went to five playoffs and three World Series just to win one, he said. Thats just to explain the difficulty of winning at that level. It was eye-opening.

The Tigers had gotten permission to interview Lombard for the open manager job earlier in the playoffs. And although Lombard made it clear that his sole focus at the time was on trying to win a ring with the Dodgers and he hadnt had time to properly research the Tigers' job, he impressed both general manager Al Avila and assistant general manager David Chadd.

David Chadd called me and said they had hired AJ Hinch, but would I have any interest in being a bench coach, Lombard said. They loved my interview. That came out of the blue because I pictured myself being with the Dodgers for many years.

George Lombard played for the Tigers in 2002.(Photo: Al Bello, Getty Images)

Having won a ring with the Dodgers, having managerial ambitions, with the mutual admiration and history he has with Hinch, and with Detroit a heck of a lot closer to his family in Georgia than Los Angeles it ended up being an easy call to accept the Tigers job.

I have so much gratitude for (Dodgers president) Andrew Friedman and (manager) Dave Roberts for giving me my first Major League coaching job, Lombard said. But they both pushed on me that it was important for me to get into a position where I could start making decisions and take on more responsibility.

And with AJ, I think hes going to be a great person for me to learn from and to teach me the Xs and Os of the game.

Detroit is a trigger point of a lot of memories for Lombard, memories from his playing days. He was traded from the Braves to the Tigers on June 19, 2002. The Braves and Tigers happened to playing each other that day in Atlanta. He just walked from the home clubhouse to the visitor's clubhouse.

Lombard has the distinction of taking batting practice for both teams, first in a Braves uniform and then in a Tigers uniform, before the same game.

Later that summer, Lombard made his first visit to Boston as a big-leaguer. He hadnt been back to New England since the summer his mother died. On July 7, with his mothers family, his grandparents, in the stands, he clubbed a massive home run off pitcher Sun Woo-Kim in the third inning that cleared the wall in center field.

That was unquestionably one of the highlights of my career," he said. "The ball hit off the cameramans leg. The trainer got the ball and his wife did a lot of artwork on it. I still have it.

That was one proud moment for my grandfather, just to see the Lombard name all over the paper. Also, that was the summer Ted Williams died. I have a picture that ran in the Boston Globe of me batting against Pedro Martinez with the flag at half-mast in the background.

And now, as best he can, in his own way, Lombard is carrying the torch of advocacy that his mother helped light 50 years ago.

All of us see things, he said. There are things weve noticed over the last year or so, starting with COVID and the racial injustices. I hope its opened up our eyes to the way we should live our life.

Lombard, above all else, wants to facilitate conversations about justice. He wants to create and sustain awareness. He does it by words and deeds. The cleats he wore last season bore the images of his mother on his left heel and civil rights leader John Lewis on his right.

We can make a difference every day and it doesnt have to be going out and marching for the civil rights movement, he said. It can be as simple as helping out one of your teammates, helping the community or just helping some kid.

We have to be more educated on the subject. I need to be better. I need to teach and overcome some of the things we are going through today. We need to be more educated on that, and thats what I take pride in doing.

Its also, from a leadership standpoint, about listening.

Great leaders are great listeners, he said. Thats where it starts. Before we can open up our minds and hearts, we need to be better listeners. We all know that. But hearing it and reemphasizing it is important.

chris.mccosky@detroitnews.com

Twitter: @cmccosky

Continue reading here:
'We all need to wake up': Advocacy, activism are part of new Tigers coach Lombard's DNA - The Detroit News

Understand the influence of COVID-19 on the DNA RNA Extraction Ki market with our analysts monitoring the situation across the globe.DNA RNA Extraction Ki market Analyasis 2021-2027

The DNA RNA Extraction Ki market report studies vital factors about the DNA RNA Extraction Ki that are essential to be understood by existing as well as latest market players. The report highlights the essential elements such as market share, profitability, production, sales, manufacturing, advertising, key market players, regional segmentation, and many more crucial aspects related to the Global DNA RNA Extraction Ki market.

Top Manufacturer Detail Qiagen, Thermo Fisher Scientific, Merck KGaA, Roche, Cytiva, Agilent, Danaher, Promega, Bio-Rad, Bioneer, Akonni Biosystems

The world, millions of people worldwide were infected with COVID-19 disease, and major countries around the world have implemented foot prohibitions and work stoppage orders. Except for the medical supplies and life support products industries, most industries have been greatly impacted, and DNA RNA Extraction Ki industries have also been greatly affected.

Get a Sample Report @:https://www.garnerinsights.com/Global-DNA-RNA-Extraction-Kit-Market-Trends-By-Regional-Analysis-America-Europe-Asia-Pacific-and-Middle-EastAfrica-Growth-Opportunity-and-Industry-Forecast-2020-2027#request-sample

Section (5 6 7): Product Type SegmentationDNA Extraction Kit, RNA Extraction Kit

Industry SegmentationHospital, Laboratory, Other

The report specifically highlights the market share, company profiles, regional outlook, product portfolio, a record of the recent developments, strategic analysis, sales, distribution chain, manufacturing, production as well as advertising, brand value, popular products, demand and supply, and other important factors related to the market to help the new entrants understand the market scenario better.

The report is segmented as follows:

By Region/Country including:

Enquire Here For Discount @https://www.garnerinsights.com/Global-DNA-RNA-Extraction-Kit-Market-Trends-By-Regional-Analysis-America-Europe-Asia-Pacific-and-Middle-EastAfrica-Growth-Opportunity-and-Industry-Forecast-2020-2027#discount

Key features of this report are:

1.It provides valuable insights into theGlobal DNA RNA Extraction Ki market.2.Provides information for the years 2021-2027.Important factors related to the market are mentioned.3.Technological advancements, government regulations, and recent developments are highlighted.4.Advertising and marketing strategies, market trends, and analysis are studied in this report.5.Growth analysis and predictions until the year 2027.6.Statistical analysis of the key players in the market is highlighted.7.Extensively researched market overview.

Other features of the report:

1.Gives a thorough analysis of the key strategies with focus on the corporate structure, R&D methods, localization strategies, production capabilities, sales and performance in various companies.2.Provides valuable insights of the product portfolio, including product planning, development and positioning.3.Analyses the role of key DNA RNA Extraction Ki market players and their partnerships, mergers and acquisitions.

View Full Report of DNA RNA Extraction Ki market@ https://garnerinsights.com/Global-DNA-RNA-Extraction-Kit-Market-Trends-By-Regional-Analysis-America-Europe-Asia-Pacific-and-Middle-EastAfrica-Growth-Opportunity-and-Industry-Forecast-2020-2027

About Us:Garner Insights is a Market Intelligence and consulting firm with an all-inclusive experience and vast knowledge of the market research industry. Our vast storage of research reports across various categories, gives you a complete view of the ever changing and developing trends and current topics worldwide. Our constant endeavor is to keep on improving our storage information by providing rich market reports and constantly improving them.

Contact Us:Mr. Kevin Thomas+1 513 549 5911 (US)+44 203 318 2846 (UK)Email: sales@garnerinsights.com

Read the rest here:
Significant Growth of DNA RNA Extraction Ki Market Will Grow at a Healthy CAGR by 2027 Along with Top Key Players Qiagen, Thermo Fisher Scientific,...

DNA Repair Drugs Market: Introduction

Read Report Overview - https://www.transparencymarketresearch.com/dna-repair-drugs-market.html

Key Drivers and Opportunities of Global DNA Repair Drugs Market

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=77165

Request for Analysis of COVID-19 Impact on DNA Repair Drugs Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=77165

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=77165

North America to Capture Major Share of Global DNA Repair Drugs Market

Pre Book DNA Repair Drugs Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=77165&ltype=S

Key Players Operating in Global DNA Repair Drugs Market

The global DNA repair drugs market is highly concentrated due to the presence of key players. A large number of manufacturers hold major share in their respective regions. Demand for technologically advaced products has increased in emerging as well as developed markets, owing to rise in prevalence of cancer. Growth strategies adopted by leading players are likely to drive the global market.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

See original here:
DNA Repair Drugs Market: Rise in prevalence of cancer among population is likely to fuel the growth of the market - BioSpace

John Henderson|The Gainesville Sun

For more than 40 years, Timothy Propes didnt know he had a father, as his mother told him he had died before Propes was born.

But over the years, he yearned to know more about his other family members.

He never knew that a DNA test would result in him finding out that his father was actually alive and livesonly an hour away from his Gainesville home, but also that he also had four sisters.

Honestly, I was still under the impression that my father had passed away before I was born, so I was hoping that I could possibly find some aunts or uncles, some relatives, the 43-year-old Propes said.

Propes and his wife decided to try out the genetic testing firm, 23andMe, which discovered that he had an aunt who was a blood relative who lived in Orlando.

He said he wasnt that excited at first, as aunts and uncles are popular relatives, not thinking that if the woman was in fact his aunt, that her brother would have been his father.

He tried reachingout to her by friending her on Facebook, but she didnt initially accept his request.

After six months, he decided to try and friend his aunts husband on Facebook to relay the message to her.

I sent him a request and he fortunately accepted it without knowing who I was, Propes said.

The man then relayed the message to his aunt.

When he accepted it, I sent him this letter explaining that, I was linked to your wife. We are relatives. She came back as my aunt.Id really like to talk to her, Propes said. And then she accepted my request.

They talked on the phone, and initially, his aunt was skeptical that her brother was his father, Propes said.

But after seeing his picture, the aunt then realized not only that Propes was her brothers son. She also knew which of her two brothers was his father.

As soon as she saw my picture, shes like, 'Oh crap, (what a resemblance), Propes said.

The aunt did not want to comment for this story, nor did Propes' father.

More feel-good stories: Over 100Whataburger drive-thru customers 'pay it forward' for 4 hours

Thrice as nice: Gulf Breeze man pays utility bills for 114 families up from 36 in 2019

Propes, who has his own children and works for Lake Butler Reception & Medical Center correctional facility, said his mother, who is no longer alive, gave birth to him at the young age of 14.

He was raised by his grandparents.

My grandparents actually adopted me because she was only 15 and she couldnt really raise me, he said. I always kept in contact with my mom. Id see her during the summer time.

Over the years, he didnt question his mom about his father as he thought he was dead.

The man she thought was my father, she thought he had died when she was pregnant, Propes said. And she really didnt talk about him too much. I didnt have anything to go by, not even the name of the man she thought it was.

But as the years passed, he yearned to learn more about the rest of his extended family, as it seemed like he just knew about his immediate family.

As I got older, curiosity kind of got the best of me, especially when I started having a family of my own, Propes said. I just kind of wanted to know a little bit about my biological history and things of that nature.

Inspiration: In a pandemic year, blind runner finishes 2,020-mile '2020 Challenge'

Propes said a couple of days after finally talking to his aunt, his father called him.

He learned that he lived in Green Cove Springs outside Jacksonville, about an hour drive from his home in Gainesville. It's also where Propes grew up.

We spoke for the first time, which went really well, Propes said. He was actually a lot calmer than Id thought hed be in that situation. We just kind of talked a little bit about my mom and the past.

In late March, Prope's father took a genetic test through23andMe, which confirmed thathe was his biological father.

He sent me a message with a screenshot of the results, Propes said. He just said, Welcome to the family, my long-lost son.

Propes said his father wanted to wait until April Fools Day to announce to his four daughters sisters Prope never knew he had that a son was also part ofthe family.

He wanted to play a prank on his daughters, Prope said. He had a little fun with it. We found out at the end of March so it wasnt too long before the family knew about it.

Propes then drove up to Green Cove Springs and met his father.

They hugged.

It was exciting, emotional, just a lot of feelings, Propes said. My wife has it on video. He was just walking out from his pier. He lives right on the water there in Green Cove Springs. We met in the front yard. We embraced. It was just surreal I guess you could say.

Tina Pearce, who also lives in the Jacksonville area, learned that Prope was her brother from the experience and has visited him several times at her fathers house.

It was kind of surreal because when my dad told us, it was on April Fools Day, so we thought he was just playing a prank, Pearce said. When we started looking at pictures it was just amazing how much he looked like our family. It was just crazy.

She said she wasnt there when her father first met Propes but she saw a video of it.

He was just kind of shocked and surprised, Pearce said. I dont think he had any idea.

Go here to see the original:
Timothy Propes lived 43 years thinking his father died before he was born. A DNA test proved he was wrong - Gainesville Sun

New York, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Viral Vector & Plasmid DNA Manufacturing Market Research Report by Type, by Indication, by Workflow, by Application, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p06007650/?utm_source=GNW

Market Statistics:The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.

1. The Global Viral Vector & Plasmid DNA Manufacturing Market is expected to grow from USD 688.42 Million in 2020 to USD 2,103.32 Million by the end of 2025.2. The Global Viral Vector & Plasmid DNA Manufacturing Market is expected to grow from EUR 603.62 Million in 2020 to EUR 1,844.23 Million by the end of 2025.3. The Global Viral Vector & Plasmid DNA Manufacturing Market is expected to grow from GBP 536.62 Million in 2020 to GBP 1,639.53 Million by the end of 2025.4. The Global Viral Vector & Plasmid DNA Manufacturing Market is expected to grow from JPY 73,472.92 Million in 2020 to JPY 224,478.60 Million by the end of 2025.5. The Global Viral Vector & Plasmid DNA Manufacturing Market is expected to grow from AUD 999.69 Million in 2020 to AUD 3,054.31 Million by the end of 2025.

Market Segmentation & Coverage:This research report categorizes the Viral Vector & Plasmid DNA Manufacturing to forecast the revenues and analyze the trends in each of the following sub-markets:

"The Adeno-Associated Virus is projected to witness the highest growth during the forecast period"

Based on Type, the Viral Vector & Plasmid DNA Manufacturing Market studied across Adeno-Associated Virus, Adenovirus, Lentivirus, and Plasmid DNA. The Lentivirus commanded the largest size in the Viral Vector & Plasmid DNA Manufacturing Market in 2020. On the other hand, the Adeno-Associated Virus is expected to grow at the fastest CAGR during the forecast period.

"The Infectious Disease is projected to witness the highest growth during the forecast period"

Based on Indication, the Viral Vector & Plasmid DNA Manufacturing Market studied across Cancer, Genetic Disorder, and Infectious Disease. The Cancer commanded the largest size in the Viral Vector & Plasmid DNA Manufacturing Market in 2020. On the other hand, the Infectious Disease is expected to grow at the fastest CAGR during the forecast period.

"The Upstream Processing is projected to witness the highest growth during the forecast period"

Based on Workflow, the Viral Vector & Plasmid DNA Manufacturing Market studied across Downstream Processing and Upstream Processing. The Downstream Processing further studied across Fill-finish and Purification. The Upstream Processing further studied across Vector Amplification & Expansion and Vector Recovery/Harvesting. The Downstream Processing commanded the largest size in the Viral Vector & Plasmid DNA Manufacturing Market in 2020. On the other hand, the Upstream Processing is expected to grow at the fastest CAGR during the forecast period.

"The Vaccinology is projected to witness the highest growth during the forecast period"

Based on Application, the Viral Vector & Plasmid DNA Manufacturing Market studied across Antisense & RNAi, Cell Therapy, Gene Therapy, and Vaccinology. The Gene Therapy commanded the largest size in the Viral Vector & Plasmid DNA Manufacturing Market in 2020. On the other hand, the Vaccinology is expected to grow at the fastest CAGR during the forecast period.

"The Research Institutes is projected to witness the highest growth during the forecast period"

Based on End User, the Viral Vector & Plasmid DNA Manufacturing Market studied across Biotech Companies and Research Institutes. The Biotech Companies commanded the largest size in the Viral Vector & Plasmid DNA Manufacturing Market in 2020. On the other hand, the Research Institutes is expected to grow at the fastest CAGR during the forecast period.

"The Asia-Pacific is projected to witness the highest growth during the forecast period"

Based on Geography, the Viral Vector & Plasmid DNA Manufacturing Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. The Americas commanded the largest size in the Viral Vector & Plasmid DNA Manufacturing Market in 2020. On the other hand, the Asia-Pacific is expected to grow at the fastest CAGR during the forecast period.

Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Viral Vector & Plasmid DNA Manufacturing Market including ABL Inc., Batavia Biosciences B.V., BioNTech IMFS GmbH, Biovian Oy, c-LEcta GmbH, Cell and Gene Therapy Catapult, Cevec Pharmaceuticals GmbH, Cobra Biologics Limited, Creative Biogene, FinVector Vision Therapies, FUJIFILM Diosynth Biotechnologies Inc., GE Healthcare, GeneOne Life Science, Inc., Genezen Laboratories, Kaneka Eurogentec S.A., Lonza Group AG, Merck KGaA, Miltenyi Biotec GmbH, Novasep Inc., Sirion-Biotech GmbH, Spark Therapeutics Inc., Thermo Fisher Scientific Inc., uniQure N.V., Vigene Biosciences, Inc., and Wuxi AppTec Co., Ltd..

Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

360iResearch FPNV Positioning Matrix:The 360iResearch FPNV Positioning Matrix evaluates and categorizes the vendors in the Viral Vector & Plasmid DNA Manufacturing Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

360iResearch Competitive Strategic Window:The 360iResearch Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:1. What is the market size and forecast of the Global Viral Vector & Plasmid DNA Manufacturing Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Viral Vector & Plasmid DNA Manufacturing Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Viral Vector & Plasmid DNA Manufacturing Market?4. What is the competitive strategic window for opportunities in the Global Viral Vector & Plasmid DNA Manufacturing Market?5. What are the technology trends and regulatory frameworks in the Global Viral Vector & Plasmid DNA Manufacturing Market?6. What are the modes and strategic moves considered suitable for entering the Global Viral Vector & Plasmid DNA Manufacturing Market?Read the full report: https://www.reportlinker.com/p06007650/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

The rest is here:
Viral Vector & Plasmid DNA Manufacturing Market Research Report by Type, by Indication, by Workflow, by Application, by End User - Global Forecast...